Johnson & Johnson logo

Johnson & Johnson

JNJ
HealthcareNYSEUnited States
234.93USD-0.50 (-0.21%)

About J&J

Johnson & Johnson, together with its subsidiaries, engages in the research, development, manufacture and sale of healthcare products worldwide.

The company operates through two primary segments.

The Innovative Medicine segment offers prescription products across various therapeutic areas, including:

  • Immunology: Rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis

  • Infectious Diseases: HIV/AIDS

  • Neuroscience: Mood disorders, neurodegenerative disorders, and schizophrenia

  • Oncology: Prostate cancer, hematologic malignancies, lung cancer, and bladder cancer

  • Cardiovascular and Metabolism: Thrombosis, diabetes, and macular degeneration

  • Pulmonary Hypertension: Pulmonary arterial hypertension

The MedTech segment includes a wide range of medical technologies and devices:

  • Electrophysiology products for heart rhythm disorders

  • Heart recovery solutions for severe coronary artery disease and cardiogenic shock

  • Circulatory restoration devices for coronary and peripheral artery diseases

  • Neurovascular care for hemorrhagic and ischemic stroke

  • Orthopaedics portfolio, including products and technologies for hips, knees, trauma, spine, and sports medicine

  • Surgical technologies for advanced and general procedures, breast aesthetics, and reconstruction

  • Vision care products, including ACUVUE contact lenses and TECNIS intraocular lenses for cataract surgery

The company distributes its products through wholesalers, hospitals, and retailers, as well as to physicians, nurses, clinics and eye care professionals.

Johnson & Johnson was founded in 1886 and is headquartered in New Brunswick, New Jersey.

J&J's Business Strategy

Johnson & Johnson (J&J) has strategically transformed into a focused healthcare company, concentrating on two primary segments: Innovative Medicine and MedTech. This shift was marked by the spin-off of its consumer health division, Kenvue, in 2023, allowing J&J to dedicate resources to high-growth, high-innovation markets.…

Available on Finplify

Free account required

Sign up free

Our Take on J&J

Pros:

Diversified Healthcare Conglomerate: J&J operates across three major segments: pharmaceuticals, medtech (medical devices), and consumer health (now separated under the Kenvue spin-off). This diversification provides a strong balance of growth, defensiveness, and cash flow stability.

Leading Pharmaceutical Portfolio: J&J’s pharma division includes major…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NYSE
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato
Employees
138,100
IPO Date
1943-01-02
ISIN
US4781601046
Website
jnj.com

Key Metrics

Market Cap
566.15BUSD
P/E Ratio (TTM)
21.33
Net Profit Margin
28.46%
Debt / Asset Ratio
0.24
Dividend Yield (TTM)
2.21%
Volume
865,290
Avg Volume
8.88M
Shares Outstanding
2.41B
Free Float
99.88%
β Beta
0.33
52W Range
141.5 - 251.7

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
4.6/5Excellent
Liquidity
3.0/5Average
Leverage
4.0/5Good
Cash Flow
4.5/5Excellent
Valuation
3.9/5Good

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on J&J

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.